Bococizumab for the treatment of hypercholesterolaemia

References

• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. ​
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(39):2999–3058. ​
   Google Scholar
• McDonagh M, Peterson K, Holzhammer B, et al. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641–53q.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Macchi C, et al. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2016;173:19–29.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discovery. 2012;11(5):367–383.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Chapman MJ, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2016.pii: ehw480. ​
   Web of Science ®Google Scholar
• Achimastos A, Alexandrides T, Alexopoulos D, et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones. 2016;15(1):8–14.
   PubMedGoogle Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–1819.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–2540.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–1590.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509.
   PubMed Web of Science ®Google Scholar
• EMA. Evolocumab. Summary of product characteristics. [cited 2016 Apr]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003766/WC500191398.pdf
   Google Scholar
• EMA. Alirocumab. Summary of product characteristics. [cited 2016 Apr]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003882/WC500194521.pdf
   Google Scholar
• Valerio MG, Velayati A, Jain D, et al. Promising new therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2016;16(5):609–618.
   PubMed Web of Science ®Google Scholar
• Levisetti M, Joh T, Wan H, et al. A phase I randomized study of a specifically engineered, pH-sensitive PCSK9 inhibitor RN317 (PF-05335810) in hypercholesterolemic subjects on statin therapy. Clin Transl Sci. 2016. doi:10.1111/cts.12430. [Epub ahead of print] ​
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Nissen SE, Rader DJ, et al. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled phase 2 study. Eur Heart J. 2016;37(17):1360–1369.
   PubMed Web of Science ®Google Scholar
• Joseph L, Robinson JG. Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis. 2015;58(1):19–31.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60–68.
   PubMed Web of Science ®Google Scholar
• Mitchell T, Chao G, Sitkoff D, et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014;350(2):412–424.
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10.
   PubMed Web of Science ®Google Scholar
• Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256–265.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discovery. 2010;9(10):767–774.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115(9):1212–1221.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Keiserman M, Codreanu C, Handa R, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014;10(8):1049–1057.
   PubMed Web of Science ®Google Scholar
• Paramarta JE, Baeten DL. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther. 2014;16(4):R160.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2011–2019.
   PubMed Web of Science ®Google Scholar
• Yoo EM, Wims LA, Chan LA, et al. Human IgG2 can form covalent dimers. J Immunol. 2003;170(6):3134–3138.
   PubMed Web of Science ®Google Scholar
• Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25(12):1369–1372.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7(9):1401–1413.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–659.
   PubMed Web of Science ®Google Scholar
• Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340(2):228–236.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA. 2008;105(6):1820–1825.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013;7:1135–1148.
   PubMed Web of Science ®Google Scholar
• Wang E, Plowchalk D, Gibiansky L, et al. Population pharmacokinetic and pharmacodynamics modeling of bococizumab (RN316/PF-04950615) in hypercholesterolemic subjects {abstract]. Atherosclerosis. 2014;235:e192–e301.
   Google Scholar
• Gumbiner B, Joh T, Udata C, et al. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin Kexin Type 9, in hypercholesterolemic subjects on high and maximal dose statins. Circulation. 2012;126:2776–2799.
   Web of Science ®Google Scholar
• Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Reviews Cardiol. 2014;11(10):563–575.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–2017.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–2353.
   PubMed Web of Science ®Google Scholar
• Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. 2016 [cited 2016 Nov 22]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor
   Google Scholar
• Ridker PM, Amarenco P, Brunell R, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the studies of PCSK9 inhibition and the reduction of vascular events (SPIRE) lipid lowering and SPIRE cardiovascular outcomes trials. Am Heart J. 2016;178:135–144.
   PubMed Web of Science ®Google Scholar
• Bergeron N, Phan BA, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–1666.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am Heart J. 2016;173:94–101.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Rathouska J, Derosa G, et al. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15(4):344–353.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182.
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin Kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation. 2013;128(9):962–969.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711–715.
   PubMed Web of Science ®Google Scholar
• Villard EF, Thedrez A, Blankenstein J, et al. PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo. An effect blunted by alirocumab. JACC Basic Transl Sci. 2016;1:419–427.
   PubMedGoogle Scholar
• Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29–36.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Macchi C, Morlotti B, et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 2014;25(5):401–406.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. Eur Heart J. 2016;37(39):2981–2989.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2016. pii: S2213-8587(16)30396-5. doi:10.1016/S2213-8587(16)30396-5. [Epub ahead of print] ​
   Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383–1391.
   PubMed Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144–2153.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743–753.
   PubMed Web of Science ®Google Scholar